文献速递脑血管病

SUMMIT MAX 随机试验:超大孔径 HiPoint 与 Vecta 抽吸取栓比较

SUMMIT MAX: A Randomized Trial of the Super Large Bore HiPoint Reperfusion System Versus Vecta System for Aspiration Thrombectomy.
PubMed 文献 · Stroke · 2025-05-21

SUMMIT MAX 是一项前瞻性、随机、对照、开放标签临床试验,纳入颈内动脉和大脑中动脉 M1 段闭塞患者 250 例,改良意向治疗人群 166 例(HiPoint 89 例、Vecta 77 例)。主要有效性终点成功再灌注(mTICI≥2b,仅用 assigned 器械,任何非研究器械使用计为失败)HiPoint 组 77.5%(69/89)vs Vecta 组 50.6%(39/77),非劣效 P<0.0001;术后 24 小时内症状性颅内出血两组相似(3.6% vs 2.7%);90 天良好临床结局(mRS≤2)HiPoint 组 50.6% vs Vecta 组 53.3%(绝对差 -2.8% [95%CI -18.2% 至 12.7%],P=0.75)。

要点

  • 主要有效性终点成功再灌注 HiPoint 组 77.5%(69/89)vs Vecta 组 50.6%(39/77),非劣效 P<0.0001。
  • 术后 24 小时内症状性颅内出血 HiPoint 组 3.6% vs Vecta 组 2.7%,两组相似。
  • 90 天良好临床结局(mRS≤2)HiPoint 组 50.6% vs Vecta 组 53.3%,绝对差 -2.8%(95%CI -18.2% 至 12.7%,P=0.75)。

核心结论

  • 在前循环大血管闭塞患者中,超大孔径 HiPoint 系统在实现成功再灌注方面非劣效于 Vecta 系统,且安全性特征相似。
  • 该研究支持超大孔径 HiPoint 系统用于机械取栓。

研究设计与样本

  • SUMMIT MAX 为前瞻性、随机、对照、开放标签临床试验,纳入颈内动脉和大脑中动脉 M1 段闭塞患者。
  • 共入组 250 例,改良意向治疗人群 166 例:HiPoint 组 89 例、Vecta 组 77 例;中位年龄 69 岁,女性 54.2%。
  • 非劣效界值为 12.5%。
  • 主要有效性终点为成功再灌注(mTICI≥2b,独立核心实验室裁定,仅使用 assigned 研究器械,任何非研究器械使用计为失败)。
  • 主要安全性终点为术后 24 小时(-8/+24)内症状性颅内出血。

主要发现

  • 成功再灌注(任何辅助治疗计为失败)HiPoint 组 77.5%(69/89)vs Vecta 组 50.6%(39/77),非劣效 P<0.0001。
  • 术后 24 小时(-8/+24)内症状性颅内出血 HiPoint 组 3.6% vs Vecta 组 2.7%,两组相似。
  • 90 天良好临床结局(mRS≤2)HiPoint 组 50.6% vs Vecta 组 53.3%,绝对差 -2.8%(95%CI -18.2% 至 12.7%),P=0.75。

关键数值与推荐

  • 非劣效界值 12.5%。
  • 主要有效性终点成功再灌注定义为 mTICI≥2b,由独立核心实验室裁定,仅使用 assigned 研究器械,任何非研究器械使用计为失败。
  • 主要安全性终点为术后 24 小时(-8/+24)内症状性颅内出血。
  • 90 天良好临床结局定义为 mRS 评分≤2。

临床怎么用

  • 对于前循环大血管闭塞(颈内动脉和大脑中动脉 M1 段)患者,超大孔径 HiPoint 系统在成功再灌注方面非劣效于 Vecta 系统,安全性特征相似。
  • 该研究支持超大孔径 HiPoint 系统用于机械取栓。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rapid and complete recanalization is a primary goal in the endovascular treatment of large vessel occlusion stroke. The effectiveness and safety of super large bore aspiration catheters (0.088″ inner diameter) for the treatment of large vessel occlusion stroke have not been demonstrated in a randomized trial. METHODS: SUMMIT MAX (A Prospective, Randomized, Controlled, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients) was a prospective, randomized, controlled, open-label clinical trial of patients with internal carotid artery and middle cerebral artery M1 occlusions, comparing the super large bore HiPoint Reperfusion system (Route 92 Medical) to the Vecta Aspiration system (Stryker Neurovascular). We hypothesized that the effectiveness and safety of the HiPoint reperfusion system were noninferior (12.5% noninferiority margin) to the Vecta Aspiration system. The primary effectiveness end point was successful reperfusion, defined as modified Treatment in Cerebral Infarction≥2b as adjudicated by an independent core lab, using only the assigned study device, with any use of a nonstudy device before or after the use of study device defined as failure. The primary safety end point was symptomatic intracranial hemorrhage within 24 hours (-8/+24) post-procedure. RESULTS: There were 250 patients enrolled of whom 166 met the criteria for the modified intent-to-treat population: 89 in HiPoint and 77 in Vecta. The median age was 69 years; 54.2% were female. Successful reperfusion with any adjunctive therapy counted as a failure was 77.5% (69/89) in the HiPoint group versus 50.6% (39/77) in the Vecta group (P<0.0001 for noninferiority). Symptomatic intracranial hemorrhage within 24 hours (-8/+24 hours) post-procedure was similar between groups (3.6% versus 2.7%, respectively). At 90 days, good clinical outcome (mRS score of ≤2) was achieved in 50.6% in the HiPoint group and 53.3% in the Vecta group (absolute difference, -2.8% [95% CI, -18.2% to 12.7%]; P=0.75). CONCLUSIONS: In this randomized trial of patients with anterior large vessel occlusion, the super large bore HiPoint system was noninferior to the Vecta system in achieving successful reperfusion, with a similar safety profile. This study supports the super large bore HiPoint system for mechanical thrombectomy. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05018650.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Nguyen TN, Dabus G, McGuinness B, et al. SUMMIT MAX: A Randomized Trial of the Super Large Bore HiPoint Reperfusion System Versus Vecta System for Aspiration Thrombectomy. Stroke. 2025. PMID: 40395106. doi:10.1161/STROKEAHA.125.051742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。